Holocene Advisors
OLMA icon

Holocene Advisors’s Olema Pharmaceuticals OLMA Stock Holding History

Holocene Advisors’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-506,001
Closed -$12.7M – 929
2025
Q4 		$12.7M Buy
+506,001
New +$9M 0.03% 315

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Holocene Advisors's OLMA Position: Q1 2026 in Review

Holocene Advisors sold out of Olema Pharmaceuticals (OLMA) in Q1 2026, closing a stake of 506,001 shares — an estimated $12.7M sold.

Holocene Advisors first reported a position in OLMA in Q4 2025 and held it in 1 quarter. The position peaked at $12.7M in Q4 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Holocene Advisors reported no remaining Olema Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Holocene Advisors sold 506,001 Olema Pharmaceuticals shares in Q1 2026, an estimated $12.7M.
  • Holocene Advisors first reported a position in Olema Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Holocene Advisors's Olema Pharmaceuticals position peaked at $12.7M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Holocene Advisors's 13F filing for Q1 2026, filed 15 May 2026.